Targeting Cytokine Signaling and Lymphocyte Traffic via Small Molecules in Inflammatory Bowel Disease: JAK Inhibitors and S1PR Agonists

• Egile Nagusiak: Tamara Pérez-Jeldres (Egilea), Christopher J. Tyler (Egilea), Joshua D. Boyer (Egilea), Thangaraj Karuppuchamy (Egilea), Andrés Yarur (Egilea), Daniel A. Giles (Egilea), Shaila Yeasmin (Egilea), Luke Lundborg (Egilea), William J. Sandborn (Egilea), Derek R. Patel (Egilea), Jesús Rivera-Nieves (Egilea)
• Formatua: Liburua
• Argitaratua: Frontiers Media S.A., 2019-03-01T00:00:00Z.
• Gaiak: article
• Sarrera elektronikoa: Connect to this object online.

The inflammatory Bowel diseases (IBDs) are a chronic, relapsing inflammatory diseases of the gastrointestinal tract with heterogeneous behavior and prognosis. The introduction of biological therapies including anti-TNF, anti-IL-12/23, and anti-integrins, has revolutionized the treatment of IBD, but...